1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
NIOX Group Plc

NIOX Group Plc

NIOX.L
NIOX Group PlcGB flagLondon Stock Exchange
58.60
GBp
+0.40
- -
246.63MMarket Cap
NIOX Group Plc
NIOX.L
(London Stock Exchange)

Recent

price

58.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
0.04
0.08
0.14
0.14
0.09
0.06
0.07
0.07
0.09
0.1
0.12
Revenue per Share
-0.08
-0.08
-0.11
-0.21
-0.2
-0.48
-0.31
-0.34
-0.13
-0.09
0.01
0.04
0.03
0.01
0.02
Basic EPS, GAAP
-0.07
-0.1
-0.1
-0.22
-0.22
-0.2
-0.18
-0.12
-0.09
-0.06
- -
0.02
0.03
0.04
0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.02
0.01
0.01
Dividend per Share
-0.2
-0.29
-0.39
-0.64
-0.63
-1.04
-1.23
-1.49
-1.5
-1.56
-1.43
-1.37
0.16
0.1
0.11
Book Value per Share
0.09
0.26
0.15
1.12
0.65
0.36
0.05
-0.3
-0.22
0.04
0.06
0.11
0.12
0.08
0.09
Tangible Book Value per Share
187
187
187
169
250
285
320
344
374
382
413
419
420
418
414
Basic Weighted Avg Shares
- -
- -
- -
- -
11
23
46
48
35
24
28
31
37
42
49
Sales/Revenue/Turnover
- -
- -
- -
- -
-625
-189.61
-177.75
-77.02
-184.39
-72.38
-12.9
5.75
12.5
18.42
21.97
Operating Margin (%)
- -
- -
- -
- -
3
5
5
4
15
9
5
5
4
4
4
Depreciation Expense
-15
-15
-20
-35
-50
-137
-99
-117
-48
-34
4
16
11
4
7
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
56.41
37.5
Effective Tax Rate (%)
- -
- -
- -
- -
-462.04
-594.37
-214.04
-242.44
-139.6
-140.17
12.9
51.44
29.08
8.85
14.37
Profit Margin (%)
17
48
28
188
175
117
59
-70
7
3
9
22
26
13
23
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
111
1
1
- -
- -
1
- -
LT Debt
19
50
30
191
410
281
225
126
85
66
67
82
84
60
68
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4.55
10.09
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.7
15.23
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.78
15.66
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-13.95%
2.12%
13.61%
Free Cash Flow
37.5%
89.09%
-14.2%
Net Income, GAAP
30.28%
45.34%
89.19%
Sales/Revenue/Turnover
23.6%
15.32%
16.51%
Total Cash Common Dividend
- -
- -
19.05%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
37
2024
- -
- -
- -
- -
42
2025
- -
- -
- -
- -
49

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.03
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.02
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
0.01
Similar Companies
Acarix AB (publ) (ACIXF)
CareRay Digital Medical Technology Co., Ltd. (688607.SS)
Bionovate Technologies Corp (BIIO)
Neovasc Inc. (NVCN.TO)
Endymed Ltd (ENDY.TA)
TruScreen Group Limited (TRU.AX)
Business
NIOX Group Plc specializes in developing and marketing medical technology globally for assessing inflammatory respiratory conditions. The company's primary offering is NIOX VERO®, a compact, user-friendly system for quantifying fractional exhaled nitric oxide (FeNO) at the point of care. This system includes a portable device along with essential consumables like sensors and disposable patient interfaces, which are crucial for accurately measuring FeNO levels in individuals. Known previously as Circassia Group Plc, the company adopted its current name in September 2022. Established in 2006, NIOX Group Plc maintains its headquarters in Oxford, United Kingdom. The firm aims to enhance asthma diagnosis and management through broader access to FeNO testing. It has reported consistent revenue growth and is developing next-generation devices, including the NIOX PRO for clinical use and the NIOX MyNO for home use.